OTCMKTS:DSRLF - DiaSorin Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 5
  • Breakdown:
  • 3 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$201.25
▲ +0.0714 (0.04%)

This chart shows the closing price for DSRLF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DiaSorin Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DSRLF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DSRLF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for DiaSorin in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $201.25.

This chart shows the closing price for DSRLF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in DiaSorin. This rating has held steady since May 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 4 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 4 sell ratings
4/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 3 sell ratings
6/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 3 sell ratings
7/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/11/2021Berenberg BankUpgradeHold ➝ Buy
3/24/2021Berenberg BankReiterated RatingHold
3/18/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight
12/10/2020BNP ParibasReiterated RatingUnderperform
12/10/2020Exane BNP ParibasReiterated RatingUnderperform
12/10/2020Kepler Capital MarketsUpgradeHold ➝ Buy
12/9/2020Morgan StanleyInitiated CoverageEqual Weight
10/30/2020Berenberg BankReiterated RatingHold
6/4/2020Berenberg BankReiterated RatingHold
5/26/2020Jefferies Financial GroupDowngradeHold ➝ Underperform
3/17/2020Berenberg BankReiterated RatingHold
(Data available from 7/26/2016 forward)
DiaSorin logo
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostic and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. It provides various immunodiagnostic platforms, including LIAISON, LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform, comprising of LIAISON MDX. DiaSorin S.p.A. has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of Point-of-Care molecular platform; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Read More

Today's Range

Now: $201.25
Low: $201.25
High: $201.25

50 Day Range

MA: $181.05
Low: $173.25
High: $201.25

52 Week Range

Now: $201.25
Low: $0.00
High: $232.00

Volume

100 shs

Average Volume

197 shs

Market Capitalization

$11.01 billion

P/E Ratio

39.15

Dividend Yield

N/A

Beta

0.48

Frequently Asked Questions

What sell-side analysts currently cover shares of DiaSorin?

The following Wall Street sell-side analysts have issued research reports on DiaSorin in the last year: Berenberg Bank, BNP Paribas, Exane BNP Paribas, Kepler Capital Markets, Morgan Stanley, and Zacks Investment Research.
View the latest analyst ratings for DSRLF.

What is the current price target for DiaSorin?

0 Wall Street analysts have set twelve-month price targets for DiaSorin in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for DiaSorin in the next year.
View the latest price targets for DSRLF.

What is the current consensus analyst rating for DiaSorin?

DiaSorin currently has 3 sell ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DSRLF, but not buy more shares or sell existing shares.
View the latest ratings for DSRLF.

What other companies compete with DiaSorin?

How do I contact DiaSorin's investor relations team?

DiaSorin's physical mailing address is Via Crescentino, Saluggia L6, 13040. The company's listed phone number is 390-161-4871 and its investor relations email address is [email protected] The official website for DiaSorin is www.diasoringroup.com.